MX2009008642A - Metodo para la identificacion de riesgo de desordenes de la tiroides. - Google Patents

Metodo para la identificacion de riesgo de desordenes de la tiroides.

Info

Publication number
MX2009008642A
MX2009008642A MX2009008642A MX2009008642A MX2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A MX 2009008642 A MX2009008642 A MX 2009008642A
Authority
MX
Mexico
Prior art keywords
patient
thyroid
risk
developing
present
Prior art date
Application number
MX2009008642A
Other languages
English (en)
Inventor
David H Margolin
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2009008642A publication Critical patent/MX2009008642A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70592—CD52
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un método para la identificación de un paciente que está en riesgo de desarrollar un desorden tiroideo que ocurre después de un tratamiento con un régimen que reduce linfocitos, el cual comprende el determinar si anticuerpos dirigidos contra la peroxidasa tiroidea o microsomas tiroideos están presentes en el paciente, en donde si los anticuerpos están presentes en el paciente entonces el paciente está en riesgo de desarrollar un desorden tiroideo. Una modalidad particular es un método para la identificación de un paciente con esclerosis múltiple que está en riesgo de desarrollar un desorden tiroideo que ocurre después de un tratamiento con un régimen que reduce células positivas a CD52, el cual comprende el determinar si anticuerpos dirigidos contra la peroxidasa tiroidea o microsomas tiroideos están presentes en el paciente, en donde si los anticuerpos están presentes en el paciente entonces el paciente está en riesgo de desarrollar un desorden tiroideo.
MX2009008642A 2007-02-16 2008-02-15 Metodo para la identificacion de riesgo de desordenes de la tiroides. MX2009008642A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90173207P 2007-02-16 2007-02-16
PCT/US2008/002047 WO2008103292A1 (en) 2007-02-16 2008-02-15 Method of identifying risk for thyroid disorder

Publications (1)

Publication Number Publication Date
MX2009008642A true MX2009008642A (es) 2009-10-20

Family

ID=39434244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008642A MX2009008642A (es) 2007-02-16 2008-02-15 Metodo para la identificacion de riesgo de desordenes de la tiroides.

Country Status (22)

Country Link
US (3) US20100136587A1 (es)
EP (2) EP2538217A1 (es)
JP (2) JP5662684B2 (es)
CN (2) CN101657721B (es)
AU (1) AU2008219097B2 (es)
BR (1) BRPI0807601B8 (es)
CA (1) CA2678199A1 (es)
CY (1) CY1118663T1 (es)
DK (1) DK2130044T3 (es)
ES (1) ES2612558T3 (es)
HK (1) HK1257419A1 (es)
HR (1) HRP20170121T1 (es)
HU (1) HUE031421T2 (es)
IL (2) IL200314A (es)
LT (1) LT2130044T (es)
MX (1) MX2009008642A (es)
PL (1) PL2130044T3 (es)
PT (1) PT2130044T (es)
RS (1) RS55636B1 (es)
RU (1) RU2013120485A (es)
SI (1) SI2130044T1 (es)
WO (1) WO2008103292A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
FR2934129B1 (fr) * 2008-07-24 2014-05-02 Oreal Procede de traitement cosmetique.
JP5833924B2 (ja) * 2008-09-19 2015-12-16 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 多発性硬化症および治療応答の同定および予測のための方法
CN106257288A (zh) * 2016-08-15 2016-12-28 余洋 一种血清TPOAb IgG4水平检测方法
EP3817761A4 (en) 2018-07-02 2021-09-08 Siemens Healthcare Diagnostics Inc. NEW IMMUNOLOGICAL DOSAGE OF THYROID PEROXIDASE AUTO-ANTIBODIES
KR102469743B1 (ko) * 2020-06-10 2022-11-22 주식회사 타이로스코프 약물 복용에 따른 갑상선 기능 모니터링 방법, 이를 수행하는 모니터링 서버 및 사용자 단말
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB2265713A (en) * 1992-05-16 1993-10-06 R S R Limited Assay for autoantibodies against thyroglobulin or thyroid peroxidase
DE19710211C2 (de) * 1997-03-12 1999-12-16 Brahms Diagnostica Gmbh Verfahren zur Bestimmung von Schilddrüsen-Autoantikörpern
GB9823397D0 (en) * 1998-10-27 1998-12-23 Rsr Ltd Assays for thyroid autoantibodies
WO2006044332A2 (en) * 2004-10-12 2006-04-27 Carantech, Inc. Animal model systems for viral pathogenesis of neurodegeneration, autoimmune demyelination, and diabetes
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)

Also Published As

Publication number Publication date
EP2130044B1 (en) 2016-10-26
ES2612558T3 (es) 2017-05-17
CN101657721B (zh) 2018-02-23
RU2009134313A (ru) 2011-03-27
US20170307629A1 (en) 2017-10-26
US20130095507A1 (en) 2013-04-18
JP6058585B2 (ja) 2017-01-11
HRP20170121T1 (hr) 2017-03-24
IL242391A (en) 2017-09-28
CN101657721A (zh) 2010-02-24
SI2130044T1 (sl) 2017-03-31
CY1118663T1 (el) 2017-07-12
PL2130044T3 (pl) 2017-04-28
HUE031421T2 (hu) 2017-07-28
RU2013120485A (ru) 2014-11-20
US10648986B2 (en) 2020-05-12
WO2008103292A1 (en) 2008-08-28
CA2678199A1 (en) 2008-08-28
AU2008219097B2 (en) 2011-06-23
CN108303546A (zh) 2018-07-20
EP2538217A1 (en) 2012-12-26
DK2130044T3 (en) 2017-02-06
AU2008219097A1 (en) 2008-08-28
LT2130044T (lt) 2017-02-10
JP2014149313A (ja) 2014-08-21
US9664688B2 (en) 2017-05-30
PT2130044T (pt) 2017-02-03
JP2010519512A (ja) 2010-06-03
IL200314A (en) 2015-11-30
BRPI0807601B8 (pt) 2021-07-27
IL200314A0 (en) 2010-04-29
EP2130044A1 (en) 2009-12-09
US20100136587A1 (en) 2010-06-03
RS55636B1 (sr) 2017-06-30
JP5662684B2 (ja) 2015-02-04
CN108303546B (zh) 2023-01-03
BRPI0807601B1 (pt) 2021-02-23
BRPI0807601A2 (pt) 2014-05-06
HK1257419A1 (zh) 2019-10-18

Similar Documents

Publication Publication Date Title
MX2009008642A (es) Metodo para la identificacion de riesgo de desordenes de la tiroides.
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
WO2009137832A3 (en) Autoantibodies in the detection and treatment of cancer
TW200616578A (en) Fluid handling devices
GB201120552D0 (en) Method and system for integrated analysis
TW200710675A (en) Methods and apparatus for resource management in a logically partitioned processing environment
HK1119244A1 (en) Detecting and predicting pre-eclampsia
MX336195B (es) Sistema de tiempo de ejecucion.
PL2129391T3 (pl) Metoda diagnostyczna
GB2505609A (en) Combining key control information in common cryptographic architecture services
WO2008034076A3 (en) Cyclophosphamide in combination with immune therapeutics
WO2010045490A3 (en) Human biomarker hypermapping for depressive disorders
EP2569445A4 (en) SCREENING ASSAYS BASED ON MAG AND / OR ABHDB FOR THE SELECTION OF INSULINATION-PROMOTING MEANS
MX342907B (es) El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
WO2012068040A3 (en) Detection of vestibular disorders based on vestibular noise
MY170810A (en) Method, device, and storage medium for setting up application runtime environment
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies
CL2011000324A1 (es) Receptaculo para el manejo de peces contagiosos o muertos que comprende un casco con una cubierta generalmente cerrada, una entrada para recibir dichos peces en un molino de pescado; y metodo para el manejo de peces contagiosos o muertos.
EP2110740A4 (en) CALCULATION PROCESSOR, INFORMATION PROCESSOR, AND CALCULATION METHOD
MX2013002652A (es) Metodos y equipos para la deteccion de una infeccion en sujetos con bajos niveles de anticuerpos especificos.
MX2014011045A (es) Metodo para seleccionar o identificar un sujeto para la terapia antagonista vib.
NZ702132A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
ES2493693A1 (es) Método para predecir o pronosticar la respuesta de un sujeto humano que padece un cáncer al tratamiento con un antagonista del receptor NK1
EP2566971A4 (en) METHOD FOR DIAGNOSIS, CLASSIFICATION AND PREDICTION OF THE RISK OF DEVELOPMENT AND IDENTIFICATION OF RESPONDER AGAINST THE TREATMENT OF RHEUMATOID ARTHRITIS
UA39026U (ru) Способ экспрессной оценки эффективности иммунизации

Legal Events

Date Code Title Description
FG Grant or registration